Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Amgen.
Advances In™: Metastatic Melanoma: Current Role and Future Potential of Oncolytic Viral Therapy
Release Date: June 30, 2019
Expiration Date: June 30, 2020
Media: Internet - based
Oncolytic viral therapy is an exciting area of development for the treatment of metastatic or advanced-stage melanoma. Therapeutic efficacy of oncolytic viruses is achieved through selective entry into cancer cells and aggressive replicative activity causing tumor lysis and promoting immune stimulation through release of cell debris and viral antigens in the tumor microenvironment. The first FDA approval for an oncolytic viral therapeutic for melanoma occurred in 2015 for talimogene laherparepvec (T-VEC) as monotherapy for unresectable or recurrent melanoma. Other viruses in early clinical trials for melanoma include the natural oncolytic herpes simplex virus, HF10; the bio-selected oncolytic and immunotherapeutic strain of coxsackievirus A21; and OBP-31, a novel, replication-competent, adenovirus serotype 5–based construct that incorporates a human telomerase reverse transcriptase gene promoter. Oncologists involved in the care of patients with melanoma may not be aware of current and emerging oncolytic viral therapies and may be uncertain how to integrate approved therapies into their clinical practice. By participating in this activity, clinicians will be better able to evaluate clinical data as they emerge regarding the efficacy and safety of novel oncolytic viral therapies.
In this activity, Advances in™ Metastatic Melanoma: Current Role and Future Potential of Oncolytic Viral Therapy, expert faculty will answer key questions regarding the evolution of oncolytic viral therapy and its growing potential in treating patients with mid to late-stage metastatic melanoma. Robert H.I. Andtbacka, MD, and Omid Hamid, MD, will discuss new data, present their perspectives on novel concepts that may affect the future, and guide participants on potential application to clinical practice.
Benefits of Participating
After participating in this activity, you should be better prepared to:
- Discuss the historical and current treatment landscape for advanced and metastatic melanoma
- Assess new viral therapeutics in melanoma and novel combination strategies with oncolytic viruses and existing immunotherapies
- Evaluate current and emerging data to select patients who may benefit from oncolytic viral therapy
- Monitor and mitigate adverse events of oncolytic viral therapy
- Describe the challenges of administering oncolytic viral therapy
CME Activity Table of Contents
- Module 1: Understanding Oncolytic Viral Therapy: Historical and Current Treatment Landscape
- Module 2: Clinical Trials of T-VEC as Monotherapy and as Combination With Immunotherapy
- Module 3: Oncolytic Viral Therapy in the Adjuvant and Neoadjuvant Setting
- Module 4: Novel Oncolytic Therapies in Clinical Trials
- Module 5: Final Remarks
- Posttest and Evaluation
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Amgen.
Instructions for This Activity and Receiving Credit
This educational program is directed toward medical oncologists and surgical oncologists who treat patients with melanoma. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals (HCPs) involved in the treatment of melanoma are also invited to participate in this activity.
Upon successful completion of this activity, you should be better prepared to:
- Assess recently reported clinical trial data on the safety and efficacy of current and emerging oncolytic viral therapies for melanoma treatment
- Apply best practices to proactively identify and mitigate the impact of treatment-related toxicities in settings where patients with melanoma are managed
- Discuss emerging data on oncolytic viral therapy in combination therapy for the management of melanoma
- Integrate emerging data on oncolytic viral therapies into the treatment landscape for melanoma
Faculty, Staff, and Planners’ Disclosures
Chief, Translational Research and Immuno-oncology
Director, Cutaneous Malignancies
The Angeles Clinic and Research Institute
Director, Experimental Therapeutics
Cedars Sinai Medical Care Foundation
Los Angeles, CA
Disclosures: Grant research support: Amgen, Arcus, Astellas, AstraZeneca, Bristol-Myers Squibb, Celldex, CytomX, Genentech, GlaxoSmithKline, Immunocore, Incyte, Iovance, Merck, Merck-Serono, MedImmune, NextCure, Novartis, Parker Institute, Pfizer, Polynoma, Regeneron, Roche; consultant: Amgen, Bristol-Myers Squibb, Merck, Novartis, Roche; speakers bureau: Amgen, Array, Bristol-Myers Squibb, Genentech, Novartis, Sanofi/Regeneron.
Chief Medical Officer
Seven and Eight Biopharmaceuticals Inc
Disclosures: : Consultant: Aduro, Merck, Novartis, Pfizer; stock/shareholder: Merck, Seven and Eight Biopharmaceuticals. Dr Andtbacka reports that his spouse is a marketing lead for a pharmaceutical company.
Employee: Dr Andtbacka is an employee of Seven and Eight Biopharmaceuticals Inc. This company is an early-stage biotech start-up and does not currently produce, market, resell, or distribute healthcare goods or services consumed by patients.
The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.
Disclosure Policy and Resolution of Conflicts of Interest (COI)
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest (COI).
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or any of the companies that provided commercial support for this program.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.